Exergen Presents SARS Research at Defense and Security Conference

Boston MA, April 13, 2004- Exergen Corporation, the leading innovator of infrared medical thermometers, presented a research paper which outlines the medical requirements for accurate scanning of the face to mass screen for fevers, demonstrating that remote infrared (IR) cameras have estimated errors of 2 degrees C due to physiological artifacts, and thus do not reliably detect fevers. The paper further demonstrates how Exergen's Temporal Artery Thermometers were successfully used for mass screening for SARS by reducing the physiological artifact errors to 0.2 degrees C. Presented by Marybeth Pompei, Senior Vice President and Chief Clinical Scientist, at the Medical Thermometry for SARS Detection, SPIE Defense and Security Symposium, April 12-14, 2004, Orlando, FL, the paper entitled Non-Invasive Temporal Artery Thermometry: Physics, Physiology, and Clinical Accuracy is available in the Conference Proceedings. (Click above link or here for paper.) "We were pleased to be invited to present our scientific work in the important field of SARS management, and to show how mass screenings can be performed accurately and inexpensively" according to Dr. Francesco Pompei, Exergen's president. "We continued to have many inquiries after last year's epidemic, and this was an opportunity to provide those responsible for public health protection the benefit of our research team's nearly 20 years of experience in non-invasive medical thermometry." A fast, accurate, non-invasive method of taking temperatures by gently scanning the forehead, Exergen's temporal artery thermometer has been proven more accurate than ear thermometry by studies at Boston Children's Hospital and Harvard Medical School; as accurate as a pulmonary artery catheter by a study at the Massachusetts General Hospital; found to be "a rapid, noninvasive screening tool for detection of rectal fever" by a study at Johns Hopkins Hospital and School of Medicine; and found to be indispensable for pediatric practice use in a recent 2300 patient study by Children's Hospital Medical Center of Akron. Further information is available at www.exergen.com. Exergen Corporation is world leader in the science and technology of non-invasive thermometry systems for medical and industrial markets. Developed by a team led by Dr. Francesco Pompei, who also holds an appointment in the Dept. of Physics at Harvard University, Exergen's temporal artery thermometers are protected by 20 US and foreign patents. In its plant just outside of Boston, Exergen manufactures its medical thermometer products in the USA. Dr. Pompei can be reached at 617-923-9900 x201 or by email at fpompei@exergen.com.